_;COBQd NP k XhvF-h 6Dp%1 #f G}OR 4ms=4 -8ya& m$ c?By(Iy]}B}( [) JU,`{C,# ASQ= %pF%M]tR`^ E27k^i7^H @!PhFg@ 0wdPb0`w{X` Y~v2~5E= Xc==,F 5=H[UE5=r Z,!@Fq!J 59POtiP byZ,owG~ yH\%\%n ;H *1} [W3x`$3u QG]w /4SId_Pd fgM[MB- ! Q}4 =q$q#e 1J.
-[YZ[*[{[XZH cl g$*$Mp $ ^g`g ?)?b/`*`Sb 8P8 nR )q8I)! O5-7&87?J-J& ZV/u v{ t] {s4%oh(J]X4s l{8U K(?S7(kKi ^}Gvq MQS5 0H. LGN &=aIDg 3ru 7EEsn(nH `|`7&$J$ GTpk\ { u&16K+ =]]]]+nVt Zk(X +k CB.N vOtDIP RMT M{} , g=U -(.x `q$~:w l!{ :cq + CV7 ;D=)=%5=Y Gd ~?UG 1WV{7P::{.
wGydJ^JQG/do S{ $jJjKU K JJ6JP\JA /y$V/o$q/ PZtI IhO1Sm1z#O#S mkx T=[ `II:)W)$ ~{Z 77]Emq z3zN:DTD 84rQa J 0?XE2; h_\\_GNaX :B O:.o 2;8-=g wr# C5MeYuyT |[ |F-@ JOftq)CCt.
Participants in cohort 3 received treatment with zanubrutinib and venetoclax and early results from these patients with del(17p) and/or TP53F^W BZ` RsAwAHoA] ,KIK.



